| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,740 | -0,57 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| ORAGENICS | 0,510 | -0,97 % | Oragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update | SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal... ► Artikel lesen | |
| LEXICON PHARMACEUTICALS | 1,955 | +1,56 % | Lexicon reports sotagliflozin data across blood pressure ranges | ||
| NANOSPHERE HEALTH SCIENCES | 0,008 | 0,00 % | Nanosphere Health Sciences Inc (2): Nanosphere Health adopts semi-annual reporting | ||
| ALIGOS THERAPEUTICS | 5,470 | +3,01 % | Aligos-Aktie +37%: Ein Vorbote für mehr? | Die Aligos-Aktie ist zum Wochenauftakt förmlich explodiert und schloss unter beachtlichen Umsätzen rund +37% höher. Für Anleger unserer Community ist das ein Déjà-vu: Bereits in der Vergangenheit haben... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,890 | -0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| ACTINOGEN | 0,030 | +14,50 % | ACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW | ||
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |